{
    "clinical_study": {
        "@rank": "78908", 
        "arm_group": {
            "arm_group_label": "Enhanced meter feature usability", 
            "arm_group_type": "Other", 
            "description": "Home diabetes monitoring by patient using provided blood glucose monitoring system."
        }, 
        "brief_summary": {
            "textblock": "This enhanced meter feature raises awareness among patients by providing additional\n      information regarding their glycemic control between Healthcare Professional visits. This\n      information may facilitate increased dialogue between patient and Healthcare Professionals\n      and can remind patients of the importance of glycemic control.\n\n      This study will evaluate a user's ability to obtain the enhanced meter feature."
        }, 
        "brief_title": "Accuracy Study for Enhanced Meter Feature", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type I or type II diabetes inclusive of the following populations:\n\n               1. Mixed insulin therapies\n\n               2. Basal insulin therapies\n\n               3. Continuous subcutaneous insulin infusion therapies\n\n               4. Multiple daily injection therapies\n\n               5. Non-insulin diabetic treatments (oral and injectable)\n\n               6. Life style (exercise and diet) diabetes management\n\n               7. New diagnosis of diabetes\n\n          -  Non diabetics\n\n          -  Able to speak and read English proficiently\n\n          -  Subjects must be willing to:\n\n               1. once a month, perform a 7 point blood glucose profile over the course of one day\n\n               2. perform fasting blood glucose tests every day\n\n               3. complete baseline and follow-up questionnaires\n\n               4. consent to baseline HbA1c assays\n\n        Exclusion Criteria:\n\n          -  Pregnant\n\n          -  Hct <20 or >60\n\n          -  Work for BGM competitor company (including, but not limited to Lifescan, Roche,\n             Abbott)\n\n          -  Homeless\n\n          -  Incarcerated\n\n          -  Mentally ill\n\n          -  Employees or students of the Research Site, including the Principal Investigator,\n             directly involved in the conduct of the protocol.\n\n          -  Has any condition that the Principal Investigator believes may interfere in the\n             subject's participation in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "133", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01885546", 
            "org_study_id": "AGAFPGM02"
        }, 
        "intervention": {
            "arm_group_label": "Enhanced meter feature usability", 
            "intervention_name": "AgaMatrix Blood Glucose Monitor", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "keyword": [
            "diabetes", 
            "glucose", 
            "glucometer"
        ], 
        "lastchanged_date": "January 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Waltham", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02453"
                }, 
                "name": "MassResearch, LLC"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Accuracy Study for the Evaluation of Obtaining an Enhanced Meter Feature Using an AgaMatrix BGMS", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "User's ability to obtain the enhanced meter feature", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01885546"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "AgaMatrix, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AgaMatrix, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}